11 May, 2026

Biotech raises $42 million to run Huntington’s disease trial

Allison DeAngelis is an East Coast biotechnology and venture reporter at STAT, where science ideas and money collide. She is also co-host of the weekly biotechnology podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01. Gene therapy startup Latus Bio has raised another $42 million to launch its first clinical trials, in […]

2 mins read

Eczema drug Kymera succeeds in first trial, could rival Dupixent

Kymera Therapeutics announced Monday that, for the second time this year, it had successfully completed an early trial of a closely watched drug intended to rival Sanofi and Regeneron’s blockbuster treatment Dupixent. The phase 1 BroADen study enrolled 22 patients with moderate to severe eczema (atopic dermatitis), all of whom took Kymera’s investigational pill, KT-621. […]

1 min read

Elevance loses the Medicare trial advantage Star Ratings

Bob Herman covers health insurance, government programs, hospitals, doctors and other suppliers – reporting how money influences these companies and shaping what we all pay for care. He is also the author of The Health Care Inc. Newsletter. You can reach Bob on the signal on Bobjherman.09. A Federal Judge of Texas canceled the Health […]

1 min read